Peptidyl-like inhibitor B3 for COVID-19

c19early.org

COVID-19 Treatment Clinical Evidence

COVID-19 involves the interplay of 500+ viral and host proteins and factors, providing many therapeutic targets. c19early analyzes 6,000+ studies for 220+ treatments—over 17 million hours of research. Only three high-profit early treatments are approved in the US. In reality, many treatments reduce risk, with 25 low-cost treatments approved across 163 countries.

Naso/oropharyngeal treatment Effective Treatment directly to the primary source of initial infection.
Healthy lifestyles Protective Exercise, sunlight, a healthy diet, and good sleep all reduce risk.
Immune support Effective Vitamins A, C, D, and zinc show reduced risk, as with other viruses.
Thermotherapy Effective Methods for increasing internal body temperature, enhancing immune system function.
Systemic agents Effective Many systemic agents reduce risk, and may be required when infection progresses.
High-profit systemic agents Conditional Effective, but with greater access and cost barriers.
Monoclonal antibodies Limited Utility Effective but rarely used—high cost, variant dependence, IV/SC admin.
Acetaminophen Harmful Increased risk of severe outcomes and mortality.
Remdesivir Harmful Increased mortality with longer followup. Increased kidney and liver injury, cardiac disorders.

Peptidyl-like inhibitor B3 may be beneficial for COVID-19 according to the study below. COVID-19 involves the interplay of 500+ viral and host proteins and factors providing many therapeutic targets. Scientists have proposed 11,000+ potential treatments. c19early.org analyzes 220+ treatments. We have not reviewed peptidyl-like inhibitor B3 in detail.

Study suggesting benefit with peptidyl-like inhibitor B3

Świderek et al., The pivotal role of β‐lactone stereochemistry in the development of SARS ‐ CoV ‐2 M ^pro inhibitors, Protein Science, doi:10.1002/pro.70680

Abstract From the arrival of the SARS‐CoV‐2 coronavirus in 2019 and its associated COVID‐19 pandemic, worldwide efforts have been focused on developing a drug to treat patients. The SARS‐CoV‐2 main protease (Mpro) is one of the main targets for drug design due to its key role in the virus replication and its distinguished ability to cleave peptides after a glutamine residue. Inspired by the knowledge of the inhibition mechanism of 20S Proteasome, this work focuses on exploring the inhibition process of SARS‐CoV‐2 M pro with a β‐lactone, as well as the impact of the stereochemistry of this compound on the stability of the enzyme:inhibitor binding formation complex. Based on molecular dynamics simulations with classical and hybrid QM/MM potentials, the free energy landscape of the mechanism of the formation of the covalent complex has been computed. The results show how one of the stereoisomers of the β‐lactone derivative forms a stable reactant non‐covalent complex in the active site of M pro . Analysis of the kinetics and thermodynamics of the inhibition process suggests that this non‐peptidyl compound can be considered a lead compound for future developments of efficient therapeutic compounds to treat patients with COVID‐19.